Skip to main content

Table 3 Characteristics of patients with different blood pressure control status

From: Clinical characteristics, imaging phenotypes and events free survival in Takayasu arteritis patients with hypertension

  Controlled
N = 95
Improved
N = 76
Failure
N = 16
P -value
Demography     
 Female (n, %) 72 (75.8%) 54 (71.1%) 12 (75.0%) 0.313
 Age (years, IQR) 31 (24–42) 34 (22–39) 29 (21–38) 0.411
Hypertensive severity (n, %)     
 Moderate 34 (35.8%) 17 (22.4%) 5 (37.5%) 0.287
 Severe 44 (45.3%) 33 (46.1%) 10 (56.3%) 0.114
Echocardiography (n, %)     
 Severe AR 9 (9.5%)* 6 (7.9%)& 4 (25.0%) < 0.001
Imaging phenotype (n, %)     
 Cluster 1 17 (17.9%) #, * 25 (32.9%) 5 (31.3%) 0.035
 Cluster 2 26 (27.4%) #,* 7 (9.2%) 2 (12.5%) < 0.001
 Cluster 3 52 (54.7%) 44 (57.9%) 9 (56.3%) 0.301
Immunosuppressive treatment     
 Glucocorticoid (prednisone, mg/day, IQR) 35 (15–40) 30 (7–40) 30 (15–40) 0.317
 Cyclophosphamide (n, %) 20 (21.2%) 13 (17.1%) 5 (31.3%) 0.289
 Leflunomide (n, %) 21 (22.1%) 14 (18.4%) 4 (25.0%) 0.376
 Biological agents (n, %) 11 (11.6%) 4 (5.3%) 2 (12.5%) 0.053
Anti-hypertensive treatment     
 Number of antihypertensive drugs (kinds, IQR) 2 (1–3) 3 (1–4) 3 (2–4) 0.074
 CCB (n, %) 69 (72.6%) 55 (72.4%) 12 (75.0%) 0.428
 ACEI/ARB (n, %) 32 (33.7%)* 18 (23.7%) 2 (12.5%) 0.029
 β-blocker (n, %) 61 (64.2%)* 39 (51.3%) 5 (31.3%) 0.033
 Diuretic (n, %) 23 (24.2%) 17 (22.4%) 6 (37.5%) 0.217
 Clonidine (n, %) 4 (4.2%)* 5 (6.6%)& 4 (25.0%) 0.015
Revascularization operation (n, %) 28 (29.5%) 25 (32.9%) 5 (31.3%) 0.221
Events free survival by the end 71.8%* 65.8% 50.0% 0.041
  1. AR aortic regurgitation; Cluster 1: involvement of abdominal aorta and/or renal artery; Cluster 2: involvement of ascending aorta, thoracic aorta, aortic arch, and its branches; Cluster 3: combined involvement of Cluster 1 and Cluster 2; CCB: calcium channel blocker; ACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; p value: comparison among patients with different blood pressure control status; #p < 0.05 for comparisons between patients with controlled and improved hypertension; *p < 0.05 for comparisons between patients with controlled and failed controlled hypertension; &p< 0.05 for comparisons between patients with improved and failed controlled hypertension